Who Paid My Doc
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome
Research payments
$1,185,659
Through program year 2025, $1,185,659 in research payments was reported against A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome, across 38 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,185,659 | 38 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- John Carter Brooklyn, NY Named on 3 payments
- James Bellor Columbia, MD Named on 3 payments
- Eric Grigsby Napa, CA Named on 2 payments
- John Carter Tampa, FL Named on 2 payments
- Jacob Aelion Jackson, TN Named on 2 payments
- Areena Swarup Mesa, AZ Named on 2 payments
- Guillermo Valenzuela Plantation, FL Named on 2 payments
- Alan Kivitz Duncansville, PA Named on 2 payments
- Maryam Khawari Katy, TX Named on 2 payments
- Paul Pickrell Austin, TX Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.